Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model.

Bruno TC, Rothwell C, Grosso JF, Getnet D, Yen HR, Durham NM, Netto G, Pardoll DM, Drake CG.

Prostate. 2012 Apr;72(5):514-22. doi: 10.1002/pros.21453. Epub 2011 Jul 14.

2.

Transforming growth factor-beta-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression.

Diener KR, Woods AE, Manavis J, Brown MP, Hayball JD.

Lab Invest. 2009 Feb;89(2):142-51. doi: 10.1038/labinvest.2008.123. Epub 2008 Dec 15.

3.

Persistence of tumor-infiltrating CD8 T cells is tumor-dependent but antigen-independent.

Olurinde MO, Shen CH, Drake A, Bai A, Chen J.

Cell Mol Immunol. 2011 Sep;8(5):415-23. doi: 10.1038/cmi.2011.18. Epub 2011 Jun 13.

4.

Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.

Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, Allison JP, Waldmann TA.

Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6187-92. doi: 10.1073/pnas.1203479109. Epub 2012 Apr 2.

5.

Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer.

Klyushnenkova EN, Riabov VB, Kouiavskaia DV, Wietsma A, Zhan M, Alexander RB.

Prostate. 2014 Oct;74(14):1423-32. doi: 10.1002/pros.22858. Epub 2014 Aug 11.

PMID:
25111463
6.

A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.

Klyushnenkova EN, Kouiavskaia DV, Parkins CJ, Caposio P, Botto S, Alexander RB, Jarvis MA.

J Immunother. 2012 Jun;35(5):390-9. doi: 10.1097/CJI.0b013e3182585d50.

7.

High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals.

Forsberg O, Carlsson B, Malmström PU, Ullenhag G, Tötterman TH, Essand M.

Prostate. 2009 Jan 1;69(1):70-81. doi: 10.1002/pros.20858.

PMID:
18814178
8.

Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.

Redmond WL, Gough MJ, Weinberg AD.

Eur J Immunol. 2009 Aug;39(8):2184-94. doi: 10.1002/eji.200939348.

9.

Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer.

Chou CK, Schietinger A, Liggitt HD, Tan X, Funk S, Freeman GJ, Ratliff TL, Greenberg NM, Greenberg PD.

J Immunol. 2012 Oct 15;189(8):3936-46. doi: 10.4049/jimmunol.1201415. Epub 2012 Sep 14.

10.

Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.

Janicki CN, Jenkinson SR, Williams NA, Morgan DJ.

Cancer Res. 2008 Apr 15;68(8):2993-3000. doi: 10.1158/0008-5472.CAN-07-5008.

11.

Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle.

Zhang Q, Yang XJ, Kundu SD, Pins M, Javonovic B, Meyer R, Kim SJ, Greenberg NM, Kuzel T, Meagher R, Guo Y, Lee C.

Mol Cancer Ther. 2006 Jul;5(7):1733-43.

12.

Effects and regulation of autoreactive CD8+ T cells in a transgenic mouse model of autoimmune hepatitis.

Zierden M, Kühnen E, Odenthal M, Dienes HP.

Gastroenterology. 2010 Sep;139(3):975-86, 986.e1-3. doi: 10.1053/j.gastro.2010.05.075. Epub 2010 Jun 2.

PMID:
20639127
13.

Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation.

Chakraborty NG, Stevens RL, Mehrotra S, Laska E, Taxel P, Sporn JR, Schauer P, Albertsen PC.

Cancer Immunol Immunother. 2003 Aug;52(8):497-505. Epub 2003 Jun 3.

PMID:
12783216
14.

Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.

Zhang Q, Yang X, Pins M, Javonovic B, Kuzel T, Kim SJ, Parijs LV, Greenberg NM, Liu V, Guo Y, Lee C.

Cancer Res. 2005 Mar 1;65(5):1761-9.

15.

Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model.

Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV, Grosso JF, Getnet D, Demarzo AM, Netto GJ, Anders R, Pardoll DM, Drake CG.

Cancer Res. 2009 May 15;69(10):4309-18. doi: 10.1158/0008-5472.CAN-08-4102. Epub 2009 May 12.

16.

CD8+ T-cell responses rapidly select for antigen-negative tumor cells in the prostate.

Bak SP, Barnkob MS, Wittrup KD, Chen J.

Cancer Immunol Res. 2013 Dec;1(6):393-401. doi: 10.1158/2326-6066.CIR-13-0109. Epub 2013 Sep 20.

17.

Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.

Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM.

Cancer Res. 2008 Feb 1;68(3):861-9. doi: 10.1158/0008-5472.CAN-07-0445.

18.

Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer.

Anderson MJ, Shafer-Weaver K, Greenberg NM, Hurwitz AA.

J Immunol. 2007 Feb 1;178(3):1268-76. Erratum in: J Immunol. 2007 Nov 15;179(10):7184.

20.

Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.

Karan D, Dubey S, Van Veldhuizen P, Holzbeierlein JM, Tawfik O, Thrasher JB.

Immunotherapy. 2011 Jun;3(6):735-46. doi: 10.2217/imt.11.59.

PMID:
21668311

Supplemental Content

Support Center